Developing a nontypeable Haemophilus influenzae (NTHi) vaccine
There is a current high demand for nontypable Haemophilus influenzae (NTHi) vaccines. Various options for the composition of such vaccines are possible. Decisions about the vaccine composition have to take into account the antigenic variability of NTHi, so even complex immunogens such as whole bacte...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2000-12, Vol.19, p.S108-S115 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S115 |
|---|---|
| container_issue | |
| container_start_page | S108 |
| container_title | Vaccine |
| container_volume | 19 |
| creator | Poolman, J.T. Bakaletz, L. Cripps, A. Denoel, P.A. Forsgren, A. Kyd, J. Lobet, Y. |
| description | There is a current high demand for nontypable
Haemophilus influenzae (NTHi) vaccines. Various options for the composition of such vaccines are possible. Decisions about the vaccine composition have to take into account the antigenic variability of NTHi, so even complex immunogens such as whole bacteria would preferentially have a tailor-made antigenic composition. We will present a summary of NTHi vaccine development, describing research efforts from SmithKline Beecham and other laboratories. Currently, major (P1, P2, P4, P5) and minor (P6, D15, TbpA/B, …) outer membrane proteins, LPS, adhesins (HMW, Hia, pili, P5) are being studied. Preclinical results with LPD, P5 (LB1) and OMP26 from our laboratories will be described including the use of animal models of otitis and lung infection. |
| doi_str_mv | 10.1016/S0264-410X(00)00288-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72555259</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X00002887</els_id><sourcerecordid>17786231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-1755dd8d8505b4b737e1bf0c83e1f6e2c55cc57db206695c2a49b4ec1d4b0c7f3</originalsourceid><addsrcrecordid>eNqFkEtLxDAUhYMoOj5-gtKV6KJ6b9I07UYRXyMMunAEdyFNbzXSl007MP56Z5xBl67O5jvnwMfYIcIZAsbnz8DjKIwQXk8ATgF4koRqg40wUSLkEpNNNvpFdtiu9x8AIAWm22wHEWMRKTFiFzc0o7JpXf0WmKBu6n7ekslKCsaGqqZ9d-XgA1cX5UD1l6Hg5HE6dqfBzFjratpnW4UpPR2sc4-93N1Or8fh5On-4fpqElqR8j5EJWWeJ3kiQWZRpoQizAqwiSAsYuJWSmulyjMOcZxKy02UZhFZzKMMrCrEHjte7bZd8zmQ73XlvKWyNDU1g9eKSym5TP8FUakk5gIXoFyBtmu876jQbecq0801gl4a1j-G9VKfBtA_hrVa9I7WB0NWUf7XWitdAJcrgBY-Zo467a2j2lLuOrK9zhv3z8U30UiKXQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17786231</pqid></control><display><type>article</type><title>Developing a nontypeable Haemophilus influenzae (NTHi) vaccine</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Poolman, J.T. ; Bakaletz, L. ; Cripps, A. ; Denoel, P.A. ; Forsgren, A. ; Kyd, J. ; Lobet, Y.</creator><contributor>Ruuskanen, O ; Chonmaitree, T ; Marchant, C ; Klein, J ; Loosemore, S ; Shinefield, H ; Dodet, B ; Dagan, R</contributor><creatorcontrib>Poolman, J.T. ; Bakaletz, L. ; Cripps, A. ; Denoel, P.A. ; Forsgren, A. ; Kyd, J. ; Lobet, Y. ; Ruuskanen, O ; Chonmaitree, T ; Marchant, C ; Klein, J ; Loosemore, S ; Shinefield, H ; Dodet, B ; Dagan, R</creatorcontrib><description>There is a current high demand for nontypable
Haemophilus influenzae (NTHi) vaccines. Various options for the composition of such vaccines are possible. Decisions about the vaccine composition have to take into account the antigenic variability of NTHi, so even complex immunogens such as whole bacteria would preferentially have a tailor-made antigenic composition. We will present a summary of NTHi vaccine development, describing research efforts from SmithKline Beecham and other laboratories. Currently, major (P1, P2, P4, P5) and minor (P6, D15, TbpA/B, …) outer membrane proteins, LPS, adhesins (HMW, Hia, pili, P5) are being studied. Preclinical results with LPD, P5 (LB1) and OMP26 from our laboratories will be described including the use of animal models of otitis and lung infection.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(00)00288-7</identifier><identifier>PMID: 11163473</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Amino Acid Sequence ; Animal models ; Animals ; Antigens, Bacterial - immunology ; Apolipoproteins - immunology ; Apolipoproteins - isolation & purification ; Apolipoproteins D ; Bacterial Outer Membrane Proteins - immunology ; Bacterial Outer Membrane Proteins - isolation & purification ; Bacterial Typing Techniques ; Chinchilla ; Haemophilus Infections - immunology ; Haemophilus Infections - microbiology ; Haemophilus Infections - prevention & control ; Haemophilus influenzae ; Haemophilus influenzae - classification ; Haemophilus influenzae - immunology ; Haemophilus Vaccines - immunology ; Humans ; LB1/fimbrin/P5 ; LPD ; Molecular Sequence Data ; Nasopharynx - immunology ; NTHi (or nontypable Haemophilus influenzae) ; OMP26 ; Otitis ; Otitis Media - immunology ; Otitis Media - microbiology ; Otitis Media - prevention & control ; Rats ; Vaccination ; Vaccine research</subject><ispartof>Vaccine, 2000-12, Vol.19, p.S108-S115</ispartof><rights>2000 Elsevier Science Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-1755dd8d8505b4b737e1bf0c83e1f6e2c55cc57db206695c2a49b4ec1d4b0c7f3</citedby><cites>FETCH-LOGICAL-c392t-1755dd8d8505b4b737e1bf0c83e1f6e2c55cc57db206695c2a49b4ec1d4b0c7f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X00002887$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,64363,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11163473$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Ruuskanen, O</contributor><contributor>Chonmaitree, T</contributor><contributor>Marchant, C</contributor><contributor>Klein, J</contributor><contributor>Loosemore, S</contributor><contributor>Shinefield, H</contributor><contributor>Dodet, B</contributor><contributor>Dagan, R</contributor><creatorcontrib>Poolman, J.T.</creatorcontrib><creatorcontrib>Bakaletz, L.</creatorcontrib><creatorcontrib>Cripps, A.</creatorcontrib><creatorcontrib>Denoel, P.A.</creatorcontrib><creatorcontrib>Forsgren, A.</creatorcontrib><creatorcontrib>Kyd, J.</creatorcontrib><creatorcontrib>Lobet, Y.</creatorcontrib><title>Developing a nontypeable Haemophilus influenzae (NTHi) vaccine</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>There is a current high demand for nontypable
Haemophilus influenzae (NTHi) vaccines. Various options for the composition of such vaccines are possible. Decisions about the vaccine composition have to take into account the antigenic variability of NTHi, so even complex immunogens such as whole bacteria would preferentially have a tailor-made antigenic composition. We will present a summary of NTHi vaccine development, describing research efforts from SmithKline Beecham and other laboratories. Currently, major (P1, P2, P4, P5) and minor (P6, D15, TbpA/B, …) outer membrane proteins, LPS, adhesins (HMW, Hia, pili, P5) are being studied. Preclinical results with LPD, P5 (LB1) and OMP26 from our laboratories will be described including the use of animal models of otitis and lung infection.</description><subject>Amino Acid Sequence</subject><subject>Animal models</subject><subject>Animals</subject><subject>Antigens, Bacterial - immunology</subject><subject>Apolipoproteins - immunology</subject><subject>Apolipoproteins - isolation & purification</subject><subject>Apolipoproteins D</subject><subject>Bacterial Outer Membrane Proteins - immunology</subject><subject>Bacterial Outer Membrane Proteins - isolation & purification</subject><subject>Bacterial Typing Techniques</subject><subject>Chinchilla</subject><subject>Haemophilus Infections - immunology</subject><subject>Haemophilus Infections - microbiology</subject><subject>Haemophilus Infections - prevention & control</subject><subject>Haemophilus influenzae</subject><subject>Haemophilus influenzae - classification</subject><subject>Haemophilus influenzae - immunology</subject><subject>Haemophilus Vaccines - immunology</subject><subject>Humans</subject><subject>LB1/fimbrin/P5</subject><subject>LPD</subject><subject>Molecular Sequence Data</subject><subject>Nasopharynx - immunology</subject><subject>NTHi (or nontypable Haemophilus influenzae)</subject><subject>OMP26</subject><subject>Otitis</subject><subject>Otitis Media - immunology</subject><subject>Otitis Media - microbiology</subject><subject>Otitis Media - prevention & control</subject><subject>Rats</subject><subject>Vaccination</subject><subject>Vaccine research</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLxDAUhYMoOj5-gtKV6KJ6b9I07UYRXyMMunAEdyFNbzXSl007MP56Z5xBl67O5jvnwMfYIcIZAsbnz8DjKIwQXk8ATgF4koRqg40wUSLkEpNNNvpFdtiu9x8AIAWm22wHEWMRKTFiFzc0o7JpXf0WmKBu6n7ekslKCsaGqqZ9d-XgA1cX5UD1l6Hg5HE6dqfBzFjratpnW4UpPR2sc4-93N1Or8fh5On-4fpqElqR8j5EJWWeJ3kiQWZRpoQizAqwiSAsYuJWSmulyjMOcZxKy02UZhFZzKMMrCrEHjte7bZd8zmQ73XlvKWyNDU1g9eKSym5TP8FUakk5gIXoFyBtmu876jQbecq0801gl4a1j-G9VKfBtA_hrVa9I7WB0NWUf7XWitdAJcrgBY-Zo467a2j2lLuOrK9zhv3z8U30UiKXQ</recordid><startdate>20001208</startdate><enddate>20001208</enddate><creator>Poolman, J.T.</creator><creator>Bakaletz, L.</creator><creator>Cripps, A.</creator><creator>Denoel, P.A.</creator><creator>Forsgren, A.</creator><creator>Kyd, J.</creator><creator>Lobet, Y.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20001208</creationdate><title>Developing a nontypeable Haemophilus influenzae (NTHi) vaccine</title><author>Poolman, J.T. ; Bakaletz, L. ; Cripps, A. ; Denoel, P.A. ; Forsgren, A. ; Kyd, J. ; Lobet, Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-1755dd8d8505b4b737e1bf0c83e1f6e2c55cc57db206695c2a49b4ec1d4b0c7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Amino Acid Sequence</topic><topic>Animal models</topic><topic>Animals</topic><topic>Antigens, Bacterial - immunology</topic><topic>Apolipoproteins - immunology</topic><topic>Apolipoproteins - isolation & purification</topic><topic>Apolipoproteins D</topic><topic>Bacterial Outer Membrane Proteins - immunology</topic><topic>Bacterial Outer Membrane Proteins - isolation & purification</topic><topic>Bacterial Typing Techniques</topic><topic>Chinchilla</topic><topic>Haemophilus Infections - immunology</topic><topic>Haemophilus Infections - microbiology</topic><topic>Haemophilus Infections - prevention & control</topic><topic>Haemophilus influenzae</topic><topic>Haemophilus influenzae - classification</topic><topic>Haemophilus influenzae - immunology</topic><topic>Haemophilus Vaccines - immunology</topic><topic>Humans</topic><topic>LB1/fimbrin/P5</topic><topic>LPD</topic><topic>Molecular Sequence Data</topic><topic>Nasopharynx - immunology</topic><topic>NTHi (or nontypable Haemophilus influenzae)</topic><topic>OMP26</topic><topic>Otitis</topic><topic>Otitis Media - immunology</topic><topic>Otitis Media - microbiology</topic><topic>Otitis Media - prevention & control</topic><topic>Rats</topic><topic>Vaccination</topic><topic>Vaccine research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poolman, J.T.</creatorcontrib><creatorcontrib>Bakaletz, L.</creatorcontrib><creatorcontrib>Cripps, A.</creatorcontrib><creatorcontrib>Denoel, P.A.</creatorcontrib><creatorcontrib>Forsgren, A.</creatorcontrib><creatorcontrib>Kyd, J.</creatorcontrib><creatorcontrib>Lobet, Y.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poolman, J.T.</au><au>Bakaletz, L.</au><au>Cripps, A.</au><au>Denoel, P.A.</au><au>Forsgren, A.</au><au>Kyd, J.</au><au>Lobet, Y.</au><au>Ruuskanen, O</au><au>Chonmaitree, T</au><au>Marchant, C</au><au>Klein, J</au><au>Loosemore, S</au><au>Shinefield, H</au><au>Dodet, B</au><au>Dagan, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Developing a nontypeable Haemophilus influenzae (NTHi) vaccine</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2000-12-08</date><risdate>2000</risdate><volume>19</volume><spage>S108</spage><epage>S115</epage><pages>S108-S115</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>There is a current high demand for nontypable
Haemophilus influenzae (NTHi) vaccines. Various options for the composition of such vaccines are possible. Decisions about the vaccine composition have to take into account the antigenic variability of NTHi, so even complex immunogens such as whole bacteria would preferentially have a tailor-made antigenic composition. We will present a summary of NTHi vaccine development, describing research efforts from SmithKline Beecham and other laboratories. Currently, major (P1, P2, P4, P5) and minor (P6, D15, TbpA/B, …) outer membrane proteins, LPS, adhesins (HMW, Hia, pili, P5) are being studied. Preclinical results with LPD, P5 (LB1) and OMP26 from our laboratories will be described including the use of animal models of otitis and lung infection.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>11163473</pmid><doi>10.1016/S0264-410X(00)00288-7</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2000-12, Vol.19, p.S108-S115 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72555259 |
| source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Amino Acid Sequence Animal models Animals Antigens, Bacterial - immunology Apolipoproteins - immunology Apolipoproteins - isolation & purification Apolipoproteins D Bacterial Outer Membrane Proteins - immunology Bacterial Outer Membrane Proteins - isolation & purification Bacterial Typing Techniques Chinchilla Haemophilus Infections - immunology Haemophilus Infections - microbiology Haemophilus Infections - prevention & control Haemophilus influenzae Haemophilus influenzae - classification Haemophilus influenzae - immunology Haemophilus Vaccines - immunology Humans LB1/fimbrin/P5 LPD Molecular Sequence Data Nasopharynx - immunology NTHi (or nontypable Haemophilus influenzae) OMP26 Otitis Otitis Media - immunology Otitis Media - microbiology Otitis Media - prevention & control Rats Vaccination Vaccine research |
| title | Developing a nontypeable Haemophilus influenzae (NTHi) vaccine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T18%3A01%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Developing%20a%20nontypeable%20Haemophilus%20influenzae%20(NTHi)%20vaccine&rft.jtitle=Vaccine&rft.au=Poolman,%20J.T.&rft.date=2000-12-08&rft.volume=19&rft.spage=S108&rft.epage=S115&rft.pages=S108-S115&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/S0264-410X(00)00288-7&rft_dat=%3Cproquest_cross%3E17786231%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17786231&rft_id=info:pmid/11163473&rft_els_id=S0264410X00002887&rfr_iscdi=true |